Compare SLNG & EQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SLNG | EQ |
|---|---|---|
| Founded | 2013 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil/Gas Transmission | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 97.4M | 89.4M |
| IPO Year | 2019 | 2018 |
| Metric | SLNG | EQ |
|---|---|---|
| Price | $4.45 | $1.23 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $8.56 |
| AVG Volume (30 Days) | 18.8K | ★ 452.1K |
| Earning Date | 11-09-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 2400.00 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $68,245,000.00 | $41,095,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $70.23 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.21 | $1.16 |
| 52 Week High | $7.07 | $6.20 |
| Indicator | SLNG | EQ |
|---|---|---|
| Relative Strength Index (RSI) | 41.01 | 34.28 |
| Support Level | $3.30 | $1.16 |
| Resistance Level | $5.01 | $1.51 |
| Average True Range (ATR) | 0.32 | 0.12 |
| MACD | -0.05 | 0.02 |
| Stochastic Oscillator | 15.58 | 18.57 |
Stabilis Solutions Inc is an energy transition company that provides turnkey clean energy production, storage, transportation, and fueling solutions using liquefied natural gas (LNG) to multiple end markets. The company provides LNG solutions to customers in diverse end markets, including aerospace, agriculture, energy, industrials, marine bunkering, mining, pipeline, remote power, and utility markets. It generates revenue by selling and delivering LNG to its customers, renting cryogenic equipment, and providing engineering and field support services. The company has a geographical presence in the United States and Mexico.
Equillium Inc is a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders with the mission to develop life-changing therapeutics for patients. It primary goal is to advance EQ504, a novel aryl hydrocarbon receptor, or AhR, modulator, into and through clinical development. The Company operates through a single operating and reportable segment focused on the business of developing novel therapies to treat severe autoimmune and inflammatory disorders, with the mission to develop life-changing therapeutics for patients. The Company manages all business activities on a consolidated basis.